Project Grant K08AI177743
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $127,705 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded May 16, 2025, with completion anticipated by November 17, 2028. The award supports basic immunological research investigating the mechanisms by which CD8+ T cell memory populations activate innate immune responses against intracellular...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $182,726 to Seattle Children's Hospital (doing business as Seattle Children's Research Institute) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 1, 2025, through August 31, 2030. This career development award supports Dr. Sara Kim's research initiative to advance understanding of Respiratory Syncytial Virus (RSV)...
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Children's Hospital Corporation (Boston Children's Hospital) a Project Grant totaling $489,500 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 25, 2025, with a completion date of June 30, 2027. This research initiative focuses on characterizing the biological role of αDβ2 as a novel complement receptor in acute lung injury associated with sepsis. The project will...
- Federal Project Grant Award Summary Seattle Children's Research Institute received a $862,347 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 20, 2026, through January 31, 2031. The grant funds research investigating the impact of respiratory syncytial virus (RSV) vaccination and preterm delivery on maternal RSV-specific peripheral and mucosal immunity. The primary...
- This federal Project Grant award of $286,791, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop pediatric-specific blood transcriptional modules (pBTMs) that capture the broad range of heterogeneous physiological states in children across diverse geographical settings. The project will construct these modules using transcriptome data from over 13,000 samples across 76 studies...
- This $402,731 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), authorized under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund a program to increase the number of next-generation physician-scientists who can apply knowledge of microbiology, immunology, and research techniques to improve reproductive, maternal, and child health. The award will support 4 physician-scientists in pediatrics or obstetrics/gynecology residency...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received a $186,224 Project Grant award from the National Institute of General Medical Sciences under the Biomedical Research and Research Training program (CFDA 93.859), effective March 1, 2026 through February 28, 2031. The award supports research investigating immunometabolic regulation of CD8 T cell dynamics in human critical illness and sepsis. The research program examines how metabolic stress—particularly abnormal...
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $324,000 to The Feinstein Institutes for Medical Research under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 5, 2025, with a completion date of July 31, 2030. The research project, titled "Comparison of the Dysregulated and Regulated Host Responses to Infection," will conduct comparative immunological studies examining the...
- Project Grant Summary Drexel University received a $554,786 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 17, 2025 through August 31, 2026. The award funds research to elucidate the mechanisms by which probiotics, specifically Lactobacillus rhamnosus (LGG), modulate antimicrobial peptide signaling and enhance innate immune responses to influenza virus...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $693,465 to Cornell University over a period from January 2025 to December 2029. The funding supports a research project titled "Mapping Infant and Adult T Cell Immunity" that aims to construct a molecular atlas of T cell development in lymph nodes and determine how cellular interactions and communication networks change during CD8+ T...
TARGETABLE PATHWAYS DRIVING SUB-OPTIMAL EARLY-LIFE CD8 T CELL RESPONSES - PROJECT SUMMARY SEVERE INFECTION IS ONE OF THE TOP THREE CAUSES OF NEONATAL MORTALITY, ACCORDING TO THE WORLD HEALTH ORGANIZATION. OF INFECTION-RELATED DEATHS, VIRUSES CAUSE 6.5% IN NEONATES AND 19.4% IN INFANTS. IN CHILDREN UNDER FIVE YEARS OF AGE, INFECTIONS WITH RESPIRATORY SYNCYTIAL VIRUS ACCOUNT FOR PARTICULARLY HIGH MORBIDITY AND MORTALITY RATES. THERE IS AN UNMET NEED TO UNDERSTAND BETTER AND MODULATE THE UNIQUE BIOLOGY OF EARLY CHILDHOOD IMMUNE CELLS, INCLUDING CYTOTOXIC CD8 T CELLS THAT ACT AS A DOUBLE-EDGED SWORD BY PROTECTING FROM INTRACELLULAR PATHOGENS INCLUDING VIRUSES WHILE ALSO CONTRIBUTING TO IMMUNOPATHOLOGY DURING SEVERE VIRAL BRONCHIOLITIS. THE FUNCTIONAL PROPERTIES AND THE MOLECULAR BASIS FOR THE UNIQUE FEATURES AND REMODELING OF CD8 T CELLS IN EARLY CHILDHOOD REMAIN LARGELY UNDEFINED IN HUMANS, LIMITING THE ADVANCEMENT OF THERAPEUTIC MODULATORS. NEONATES HAVE LOWER CD8 T COUNTS THAN ADULTS, AND THEIR CD8 T CELLS HAVE A SHORTER LIFE SPAN. MOREOVER, STUDIES IN THE FIELD HAVE FOUND THAT NEONATAL CD8 T CELLS UNDERGO RAPID PROLIFERATION AND TERMINAL DIFFERENTIATION AS EFFECTOR CELLS AT THE EXPENSE OF FORMING LONG-LIVED MEMORY CELLS. BOTH NEONATES AND PATIENTS WITH AN IMMUNE DEFICIENCY CALLED ACTIVATED PI3K-DELTA SYNDROME (APDS) SUFFER FROM SEVERE VIRAL INFECTIONS AND HAVE SIMILARLY ATYPICAL CD8 T CELL FUNCTION. WE HYPOTHESIZE THAT EARLY-LIFE CD8 T CELLS HAVE A DECREASED THRESHOLD FOR PI3K/MTOR ACTIVATION, WHICH ENHANCES EFFECTOR ACTIVITY AND AUGMENTS SHORT-LIVED EFFECTOR CYTOTOXIC T CELL FATES THAT CAN CONTRIBUTE TO IMMUNOPATHOLOGY IN SEVERE VIRAL BRONCHIOLITIS. BY COMPARING HUMAN NEONATAL, CHILD, YOUNG ADULT, AND MODERATE VS. SEVERE RSV BRONCHIOLITIS PATIENT CD8 T CELLS IN VITRO, AIM 1 WILL DEFINE MECHANISMS DRIVING INCREASED PROLIFERATION, GLYCOLYSIS, AND CELL DEATH IN EARLY-LIFE CD8 T CELLS AND AIM 2 WILL DETERMINE ROLES OF PI3K/MTOR PATHWAYS IN T CELL FUNCTION DURING RSV BRONCHIOLITIS AND THEIR RELATIONSHIP WITH DISEASE SEVERITY. THIS RESEARCH WILL LEAD TO FURTHER INSIGHTS INTO HOW EARLY-LIFE CD8 T CELLS DIFFER FUNCTIONALLY FROM THOSE OF ADULTS AND WHAT PATHWAYS COULD SERVE AS TARGETS FOR INTERVENTIONS TO IMPROVE IMMUNE RESPONSES AND OUTCOMES OF SEVERE EARLY-LIFE INFECTION. NINA BRODSKY, M.D., IS AN ASSISTANT PROFESSOR IN PEDIATRIC CRITICAL CARE AT YALE UNIVERSITY SCHOOL OF MEDICINE. HER CAREER GOAL IS TO BECOME AN INDEPENDENT PRINCIPAL INVESTIGATOR LEADING TRANSLATIONAL RESEARCH EFFORTS AND TO BECOME PROFICIENT IN DEVELOPING TARGETED TRANSLATIONAL THERAPIES TO IMPROVE OUTCOMES FOR PATIENTS WHO SUFFER FROM SEVERE INFECTION AND IMMUNE-MEDIATED DISEASES. THIS CAREER DEVELOPMENT AWARD WILL ALLOW DR. BRODSKY TO 1) HONE HER SKILLS IN IMMUNOLOGIC, OMICS, AND TRANSLATIONAL RESEARCH METHODS UNDER THE DIRECTION OF A MENTORING TEAM THAT IS AT THE FOREFRONT OF RESEARCH IN T CELL FUNCTION, SIGNALING AND METABOLISM AND 2) IDENTIFY PROMISING MOLECULAR TARGETS FOR INTERVENTION TO IMPROVE OUTCOMES OF SEVERE INFECTION FOR HER FUTURE RESEARCH.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $195.1k | 8/13/25 | ||
| Not listed | $195.1k | 8/2/24 |